Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Statin Therapy to Improve Prostate Cancer Outcomes: Who, When, and for How Long?

Allott EH, Freeman MR, Freedland SJ.

Eur Urol. 2018 Aug 31. pii: S0302-2838(18)30597-9. doi: 10.1016/j.eururo.2018.08.012. [Epub ahead of print] No abstract available.

PMID:
30177293
2.

Early-Life Alcohol Intake and High-Grade Prostate Cancer: Results from an Equal-Access, Racially Diverse Biopsy Cohort.

Michael J, Howard LE, Markt SC, De Hoedt A, Bailey C, Mucci LA, Freedland SJ, Allott EH.

Cancer Prev Res (Phila). 2018 Oct;11(10):621-628. doi: 10.1158/1940-6207.CAPR-18-0057. Epub 2018 Aug 23.

PMID:
30139875
3.

TP53 protein levels, RNA-based pathway assessment, and race among invasive breast cancer cases.

Williams LA, Butler EN, Sun X, Allott EH, Cohen SM, Fuller AM, Hoadley KA, Perou CM, Geradts J, Olshan AF, Troester MA.

NPJ Breast Cancer. 2018 Jun 25;4:13. doi: 10.1038/s41523-018-0067-5. eCollection 2018.

4.

Serum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer.

Allott EH, Masko EM, Freedland AR, Macias E, Pelton K, Solomon KR, Mostaghel EA, Thomas GV, Pizzo SV, Freeman MR, Freedland SJ.

Prostate Cancer Prostatic Dis. 2018 Jun;21(2):196-203. doi: 10.1038/s41391-018-0045-x. Epub 2018 May 23.

PMID:
29795142
5.

Statin use, high cholesterol and prostate cancer progression; results from HCaP-NC.

Allott EH, Farnan L, Steck SE, Song L, Arab L, Su LJ, Fontham ETH, Mohler JL, Bensen JT.

Prostate. 2018 Aug;78(11):857-864. doi: 10.1002/pros.23644. Epub 2018 May 1.

PMID:
29717502
6.

Geographic Differences in Baseline Prostate Inflammation and Relationship with Subsequent Prostate Cancer Risk: Results from the Multinational REDUCE Trial.

Allott EH, Markt SC, Howard LE, Vidal AC, Moreira DM, Castro-Santamaria R, Andriole GL, Mucci LA, Freedland SJ.

Cancer Epidemiol Biomarkers Prev. 2018 Jul;27(7):783-789. doi: 10.1158/1055-9965.EPI-18-0076. Epub 2018 Apr 18.

PMID:
29669727
7.

PAM50 and Risk of Recurrence Scores for Interval Breast Cancers.

Puvanesarajah S, Nyante SJ, Kuzmiak CM, Chen M, Tse CK, Sun X, Allott EH, Kirk EL, Carey LA, Perou CM, Olshan AF, Henderson LM, Troester MA.

Cancer Prev Res (Phila). 2018 Jun;11(6):327-336. doi: 10.1158/1940-6207.CAPR-17-0368. Epub 2018 Apr 5.

8.

Frequency of breast cancer subtypes among African American women in the AMBER consortium.

Allott EH, Geradts J, Cohen SM, Khoury T, Zirpoli GR, Bshara W, Davis W, Omilian A, Nair P, Ondracek RP, Cheng TD, Miller CR, Hwang H, Thorne LB, O'Connor S, Bethea TN, Bell ME, Hu Z, Li Y, Kirk EL, Sun X, Ruiz-Narvaez EA, Perou CM, Palmer JR, Olshan AF, Ambrosone CB, Troester MA.

Breast Cancer Res. 2018 Feb 6;20(1):12. doi: 10.1186/s13058-018-0939-5.

9.

Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study.

Jamnagerwalla J, Howard LE, Allott EH, Vidal AC, Moreira DM, Castro-Santamaria R, Andriole GL, Freeman MR, Freedland SJ.

Prostate Cancer Prostatic Dis. 2018 Jun;21(2):252-259. doi: 10.1038/s41391-017-0030-9. Epub 2017 Dec 27.

10.

Translating Mechanism-Based Strategies to Break the Obesity-Cancer Link: A Narrative Review.

Smith LA, O'Flanagan CH, Bowers LW, Allott EH, Hursting SD.

J Acad Nutr Diet. 2018 Apr;118(4):652-667. doi: 10.1016/j.jand.2017.08.112.

PMID:
29102513
11.

Biology and Etiology of Young-Onset Breast Cancers among Premenopausal African American Women: Results from the AMBER Consortium.

Chollet-Hinton L, Olshan AF, Nichols HB, Anders CK, Lund JL, Allott EH, Bethea TN, Hong CC, Cohen SM, Khoury T, Zirpoli GR, Borges VF, Rosenberg LA, Bandera EV, Ambrosone CB, Palmer JR, Troester MA.

Cancer Epidemiol Biomarkers Prev. 2017 Dec;26(12):1722-1729. doi: 10.1158/1055-9965.EPI-17-0450. Epub 2017 Sep 13.

PMID:
28903991
12.

Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study.

Troester MA, Sun X, Allott EH, Geradts J, Cohen SM, Tse CK, Kirk EL, Thorne LB, Mathews M, Li Y, Hu Z, Robinson WR, Hoadley KA, Olopade OI, Reeder-Hayes KE, Earp HS, Olshan AF, Carey LA, Perou CM.

J Natl Cancer Inst. 2018 Feb 1;110(2). doi: 10.1093/jnci/djx135.

13.

Statin Use, Serum Lipids, and Prostate Inflammation in Men with a Negative Prostate Biopsy: Results from the REDUCE Trial.

Allott EH, Howard LE, Vidal AC, Moreira DM, Castro-Santamaria R, Andriole GL, Freedland SJ.

Cancer Prev Res (Phila). 2017 Jun;10(6):319-326. doi: 10.1158/1940-6207.CAPR-17-0019. Epub 2017 May 9.

14.

Impact of carbohydrate restriction in the context of obesity on prostate tumor growth in the Hi-Myc transgenic mouse model.

Allott EH, Macias E, Sanders S, Knudsen BS, Thomas GV, Hursting SD, Freedland SJ.

Prostate Cancer Prostatic Dis. 2017 Jun;20(2):165-171. doi: 10.1038/pcan.2016.73. Epub 2017 Feb 28.

15.

The current evidence on statin use and prostate cancer prevention: are we there yet?

Alfaqih MA, Allott EH, Hamilton RJ, Freeman MR, Freedland SJ.

Nat Rev Urol. 2017 Feb;14(2):107-119. doi: 10.1038/nrurol.2016.199. Epub 2016 Oct 25. Review.

16.

Saturated fat intake and prostate cancer aggressiveness: results from the population-based North Carolina-Louisiana Prostate Cancer Project.

Allott EH, Arab L, Su LJ, Farnan L, Fontham ET, Mohler JL, Bensen JT, Steck SE.

Prostate Cancer Prostatic Dis. 2017 Mar;20(1):48-54. doi: 10.1038/pcan.2016.39. Epub 2016 Sep 6.

PMID:
27595916
17.

Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification.

Allott EH, Geradts J, Sun X, Cohen SM, Zirpoli GR, Khoury T, Bshara W, Chen M, Sherman ME, Palmer JR, Ambrosone CB, Olshan AF, Troester MA.

Breast Cancer Res. 2016 Jun 28;18(1):68. doi: 10.1186/s13058-016-0725-1.

18.

Statin Use and Prostate Cancer Aggressiveness: Results from the Population-Based North Carolina-Louisiana Prostate Cancer Project.

Allott EH, Farnan L, Steck SE, Arab L, Su LJ, Mishel M, Fontham ET, Mohler JL, Bensen JT.

Cancer Epidemiol Biomarkers Prev. 2016 Apr;25(4):670-7. doi: 10.1158/1055-9965.EPI-15-0631. Epub 2016 Jan 27.

19.

Racial Differences in the Association Between Preoperative Serum Cholesterol and Prostate Cancer Recurrence: Results from the SEARCH Database.

Allott EH, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ.

Cancer Epidemiol Biomarkers Prev. 2016 Mar;25(3):547-54. doi: 10.1158/1055-9965.EPI-15-0876. Epub 2016 Jan 25.

20.

Performance of Three-Biomarker Immunohistochemistry for Intrinsic Breast Cancer Subtyping in the AMBER Consortium.

Allott EH, Cohen SM, Geradts J, Sun X, Khoury T, Bshara W, Zirpoli GR, Miller CR, Hwang H, Thorne LB, O'Connor S, Tse CK, Bell MB, Hu Z, Li Y, Kirk EL, Bethea TN, Perou CM, Palmer JR, Ambrosone CB, Olshan AF, Troester MA.

Cancer Epidemiol Biomarkers Prev. 2016 Mar;25(3):470-8. doi: 10.1158/1055-9965.EPI-15-0874. Epub 2015 Dec 28.

21.

Obesity and cancer: mechanistic insights from transdisciplinary studies.

Allott EH, Hursting SD.

Endocr Relat Cancer. 2015 Dec;22(6):R365-86. doi: 10.1530/ERC-15-0400. Epub 2015 Sep 15. Review.

22.

Is PSA related to serum cholesterol and does the relationship differ between black and white men?

Zapata D, Howard LE, Allott EH, Hamilton RJ, Goldberg K, Freedland SJ.

Prostate. 2015 Dec;75(16):1877-85. doi: 10.1002/pros.23069. Epub 2015 Sep 1.

PMID:
26332663
23.

Increased biodiversity in the environment improves the humoral response of rats.

Pi C, Allott EH, Ren D, Poulton S, Lee SY, Perkins S, Everett ML, Holzknecht ZE, Lin SS, Parker W.

PLoS One. 2015 Apr 8;10(4):e0120255. doi: 10.1371/journal.pone.0120255. eCollection 2015.

24.

Carbohydrate intake, glycemic index and prostate cancer risk.

Vidal AC, Williams CD, Allott EH, Howard LE, Grant DJ, McPhail M, Sourbeer KN, Hwa LP, Boffetta P, Hoyo C, Freedland SJ.

Prostate. 2015 Mar 1;75(4):430-9. doi: 10.1002/pros.22929. Epub 2014 Nov 21.

25.

Serum lipid profile and risk of prostate cancer recurrence: Results from the SEARCH database.

Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Freedland SJ.

Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2349-56. doi: 10.1158/1055-9965.EPI-14-0458. Epub 2014 Oct 10.

26.

Non-steroidal anti-inflammatory drug use, hormone receptor status, and breast cancer-specific mortality in the Carolina Breast Cancer Study.

Allott EH, Tse CK, Olshan AF, Carey LA, Moorman PG, Troester MA.

Breast Cancer Res Treat. 2014 Sep;147(2):415-21. doi: 10.1007/s10549-014-3099-z. Epub 2014 Aug 24.

27.

Racial differences in adipose tissue distribution and risk of aggressive prostate cancer among men undergoing radiotherapy.

Allott EH, Howard LE, Song HJ, Sourbeer KN, Koontz BF, Salama JK, Freedland SJ.

Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2404-12. doi: 10.1158/1055-9965.EPI-14-0236. Epub 2014 Aug 21.

28.

Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.

Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Freedland SJ.

BJU Int. 2014 Nov;114(5):661-6. doi: 10.1111/bju.12720. Epub 2014 May 8.

29.

Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database.

Allott EH, Abern MR, Gerber L, Keto CJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Moorman PG, Freedland SJ.

Prostate Cancer Prostatic Dis. 2013 Dec;16(4):391-7. doi: 10.1038/pcan.2013.48. Epub 2013 Oct 8.

30.

Mechanistic targets and phytochemical strategies for breaking the obesity-cancer link.

Ford NA, Lashinger LM, Allott EH, Hursting SD.

Front Oncol. 2013 Aug 19;3:209. doi: 10.3389/fonc.2013.00209. eCollection 2013.

31.

Words of wisdom. Re: Dysregulation of cholesterol homeostasis in human prostate cancer through loss of ABCA1.

Solomon KR, Allott EH, Freeman MR, Freedland SJ.

Eur Urol. 2013 Jun;63(6):1128-9. doi: 10.1016/j.eururo.2013.03.017. No abstract available.

32.

The effect of dietary sodium and fructose intake on urine and serum parameters of stone formation in a pediatric mouse model: a pilot study.

Ross SS, Masko EM, Abern MR, Allott EH, Routh JC, Wiener JS, Preminger GM, Freedland SJ, Lipkin ME.

J Urol. 2013 Oct;190(4 Suppl):1484-9. doi: 10.1016/j.juro.2013.02.3199. Epub 2013 Mar 7.

PMID:
23473903
33.

Elevated Tumor Expression of PAI-1 and SNAI2 in Obese Esophageal Adenocarcinoma Patients and Impact on Prognosis.

Allott EH, Morine MJ, Lysaght J, McGarrigle SA, Donohoe CL, Reynolds JV, Roche HM, Pidgeon GP.

Clin Transl Gastroenterol. 2012 Apr 19;3:e12. doi: 10.1038/ctg.2012.5.

34.

Obesity and prostate cancer: weighing the evidence.

Allott EH, Masko EM, Freedland SJ.

Eur Urol. 2013 May;63(5):800-9. doi: 10.1016/j.eururo.2012.11.013. Epub 2012 Nov 15. Review.

35.

The relationship between nutrition and prostate cancer: is more always better?

Masko EM, Allott EH, Freedland SJ.

Eur Urol. 2013 May;63(5):810-20. doi: 10.1016/j.eururo.2012.11.012. Epub 2012 Nov 15. Review.

36.

Words of wisdom. Re: Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors.

Allott EH, Freedland SJ.

Eur Urol. 2013 Jan;63(1):178-9. doi: 10.1016/j.eururo.2012.10.028. No abstract available.

PMID:
23218490
37.

Associations between Intake of Folate, Methionine, and Vitamins B-12, B-6 and Prostate Cancer Risk in American Veterans.

Vidal AC, Grant DJ, Williams CD, Masko E, Allott EH, Shuler K, McPhail M, Gaines A, Calloway E, Gerber L, Chi JT, Freedland SJ, Hoyo C.

J Cancer Epidemiol. 2012;2012:957467. doi: 10.1155/2012/957467. Epub 2012 Aug 9.

38.

The SGBS cell strain as a model for the in vitro study of obesity and cancer.

Allott EH, Oliver E, Lysaght J, Gray SG, Reynolds JV, Roche HM, Pidgeon GP.

Clin Transl Oncol. 2012 Oct;14(10):774-82. doi: 10.1007/s12094-012-0863-6. Epub 2012 Aug 2.

PMID:
22855155
39.

C-reactive protein as a prognostic marker FOR mCRPC.

Abern MR, Allott EH, Freedland SJ.

BJU Int. 2012 Dec;110(11 Pt B):E469. doi: 10.1111/j.1464-410X.2012.11156.x. Epub 2012 Apr 23. No abstract available.

40.

MMP9 expression in oesophageal adenocarcinoma is upregulated with visceral obesity and is associated with poor tumour differentiation.

Allott EH, Lysaght J, Cathcart MC, Donohoe CL, Cummins R, McGarrigle SA, Kay E, Reynolds JV, Pidgeon GP.

Mol Carcinog. 2013 Feb;52(2):144-54. doi: 10.1002/mc.21840. Epub 2011 Nov 28.

PMID:
22121096
41.

Pro-inflammatory and tumour proliferative properties of excess visceral adipose tissue.

Lysaght J, van der Stok EP, Allott EH, Casey R, Donohoe CL, Howard JM, McGarrigle SA, Ravi N, Reynolds JV, Pidgeon GP.

Cancer Lett. 2011 Dec 15;312(1):62-72. doi: 10.1016/j.canlet.2011.07.034. Epub 2011 Aug 11.

PMID:
21890265
42.

T lymphocyte activation in visceral adipose tissue of patients with oesophageal adenocarcinoma.

Lysaght J, Allott EH, Donohoe CL, Howard JM, Pidgeon GP, Reynolds JV.

Br J Surg. 2011 Jul;98(7):964-74. doi: 10.1002/bjs.7498. Epub 2011 Apr 21.

PMID:
21520028
43.

Replicated genetic evidence supports a role for HOMER2 in schizophrenia.

Gilks WP, Allott EH, Donohoe G, Cummings E; International Schizophrenia Consortium, Gill M, Corvin AP, Morris DW.

Neurosci Lett. 2010 Jan 14;468(3):229-33. doi: 10.1016/j.neulet.2009.11.003. Epub 2009 Nov 13.

PMID:
19914345

Supplemental Content

Loading ...
Support Center